Avadel Pharmaceu Stock Price, News & Analysis

Avadel Pharmaceuticals (Nasdaq: AVDL) has entered an exclusive collaboration with the AASM Foundation to support the 2022 Young Investigators Research Forum (YIRF), which offers scholarships and training for early career sleep researchers. This initiative, ongoing since 2009, aims to enhance skills in sleep research and funding opportunities. The partnership highlights Avadel's commitment to advancing sleep science, which is critical for health, especially in conditions like narcolepsy. The forum will engage participants at the upcoming SLEEP 2022 conference in June.

Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced that CEO Greg Divis and CFO Tom McHugh will participate in a fireside chat at the Jefferies Healthcare Conference on June 9 at 4:00 p.m. E.T.

The event will be available via live webcast and archived for 90 days on Avadel’s Investor Relations website. The company focuses on transforming medicines, with its lead drug candidate FT218, a once-nightly formulation for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy.

Avadel Pharmaceuticals (Nasdaq: AVDL) announced the presentation of clinical data for FT218 at the 36th Annual Meeting of the Associated Professional Sleep Societies from June 4-8, 2022. FT218 is an investigational sodium oxybate formulation aimed at treating excessive daytime sleepiness and cataplexy in narcolepsy patients. The presentations will include interim data from the RESTORE study, highlighting dosing and patient preferences. FT218 has shown promising results in prior trials, and an FDA marketing application is currently under review.

Avadel Pharmaceuticals plc (Nasdaq: AVDL) has announced that CEO Greg Divis will participate in a fireside chat at the H.C. Wainwright Global Investment Conference on May 25 at 8:30 a.m. E.T. This event aims to share insights into the company's innovative biopharmaceutical solutions. A live webcast and an archived recording will be available on the company's Investor Relations website for 90 days following the conference. Avadel focuses on developing medications for challenges faced by patients, notably their lead candidate, FT218, designed for narcolepsy treatment.

Avadel Pharmaceuticals provided an update on the FDA review of its NDA for FT218, aimed at managing narcolepsy symptoms. The FDA has no outstanding questions regarding the application, paving the way for a potential commercial launch. Interim results from the RESTORE study showed a significant patient preference for FT218's once-at-bedtime dosage over the twice-nightly regimen, with 94.3% of participants expressing a preference. The company's financial results indicated a net loss of $26.4 million for Q1 2022, up from $13.4 million in 2021, alongside increased R&D and SG&A expenses.

Avadel Pharmaceuticals (Nasdaq: AVDL) announced a conference call on May 9, 2022, at 8:30 a.m. ET to discuss Q1 financial results ending March 31, 2022. Investors can join the call by dialing (844) 388-0559 (U.S. and Canada) or (216) 562-0393 (International), using conference ID 8183841. The call will also be available via a live webcast on the company's investor relations site, with an archived replay for 90 days. Avadel focuses on innovative treatments, notably its lead drug candidate FT218 for narcolepsy-related symptoms.

Avadel Pharmaceuticals (Nasdaq: AVDL) addressed recent trading volatility and a brief trading halt of its shares, clarifying that no new information regarding the FT218 NDA review has surfaced. CEO Greg Divis emphasized ongoing launch preparations for FT218, a sodium oxybate formulation aimed at treating narcolepsy. The FDA granted FT218 Orphan Drug Designation in 2018 due to its potential safety advantages. Avadel aims to improve narcolepsy treatment with this investigational agent, which demonstrated significant results in Phase 3 trials.

Avadel Pharmaceuticals (Nasdaq: AVDL) announced interim results from its RESTORE study at the 2022 AAN Meeting. The study evaluated patient preferences regarding FT218, a once-nightly formulation of sodium oxybate for narcolepsy. Findings revealed 94.3% (33/35) of participants preferred FT218 over the twice-nightly dosing regimen. Additionally, nocturnal adverse events highlighted issues with the second dose, with 63% of participants missing it, causing worsened symptoms. FT218 has the potential to significantly ease the burden on narcolepsy patients if approved.

Avadel Pharmaceuticals (Nasdaq: AVDL) announced positive secondary endpoint results from its Phase 3 REST-ON trial of FT218, an investigational sodium oxybate formulation for narcolepsy. Published in CNS Drugs, the data demonstrate FT218's ability to improve nighttime sleep disruptions significantly compared to placebo. Key findings show FT218 led to fewer nocturnal arousals and improved sleep quality across various doses. The trial supports FT218's potential as an effective treatment for excessive daytime sleepiness and cataplexy, with a marketing application currently under review by the FDA.